Advertisement

Antibacterial Therapy: Effect on Healing and Relapse of Peptic Ulcer Disease

  • G. Börsch

Abstract

Helicobacter pylori (formerly Campylobacter pylori, H. pylori, HP) is rapidly evolving as the single most important factor in the pathogenesis of ulcer disease, at least gastritis-associated duodenal ulcer disease [13]. Unlike the underlying genetic predispositions of this condition, H. pylori has the tremendous practical advantage of being a treatable condition.

Keywords

Duodenal Ulcer Gastric Ulcer Peptic Ulcer Disease Ulcer Healing Pylorus State 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bayerdörffer E, Ottenjann R (1988) The role of antibiotics in Campylobacter pylori associated peptic ulcer disease. Scand J Gastroenterol [Suppl 142] 23:93–100.CrossRefGoogle Scholar
  2. 2.
    Bayerdörffer E, Kasper G, Pirlet T, Sommer A, Ottenjann R (1987) Ofloxacin in der Therapie Campylobacter-pylori-positiver ulcera duodeni. Dtsch Med Wochenschr 112:1407–1411.PubMedCrossRefGoogle Scholar
  3. 3.
    Bayerdörffer E, Pirlet T, Sommer A, Kasper G, Ottenjann R (1988) Ofloxacin in der Therapie “resistenter” Ulcera duodeni. Z Gastroenterol 26:155–159.PubMedGoogle Scholar
  4. 4.
    Bianci Porro G, Lazzaroni M (1988) Campylobacter pylori and ulcer recurrence. Lancet 1:593.CrossRefGoogle Scholar
  5. 5.
    Bianci Porro G, Lazzaroni M (1989) Campylobacter pylori and peptic ulcer therapy. Gastroenterol Clin Biol 13:107 B–111 B.Google Scholar
  6. 6.
    Borody T, Cole P, Noonan S, Morgan A, Ossip G, Maysay J, Brandi S (1988) Long-term Campylobacter recurrence post eradication. Gastroenterology 94:A 43.Google Scholar
  7. 7.
    Börsch G (1987) Campylobacter pylori: new and renewed insights into gastritis-associated ulcer disease (GAUD). Hepatogastroenterology 34:191–193.PubMedGoogle Scholar
  8. 8.
    Börsch G (1989) Ist Campylobacter pylori der Erreger der Ulkuskrankheit? Pro. Z Gastroenterol 27:121–126.PubMedGoogle Scholar
  9. 9.
    Börsch G, Wegener M, Reitemeyer E, Mai U, Opferkuch W (1989) Clinical results and medium term follow-up studies after eradication of Campylobacter pylori. In: Mégraud F, Lamouliatte H (eds) Gastroduodenal pathology and Campylobacter pylori. Elsevier, Amsterdam, p 599.Google Scholar
  10. 10.
    Coghlan JG, Gilligan D, Humphreys H, McKenna D, Dooley C, Sweeney E, Keane C, O’Morain C (1987) Campylobacter pylori and recurrence of duodenal ulcers — a 12-month followup study. Lancet II: 1109–1111.CrossRefGoogle Scholar
  11. 11.
    Coghlan JG, Tobin A, O’Morain C (1989) Campylobacter pylori and ulcer treatment. In: Rathbone BJ, Heatley RV (eds) Campylobacter pylori and gastroduodenal disease. Blackwell, Oxford, p 232.Google Scholar
  12. 12.
    Eberhardt R, Kasper G, Dettmer A, Höchter W, Hagena D (1988) Wirkung von Wismutsubsalicylat versus Cimetidin auf Campylobacter pylori, Ulkusheilung und-rezidivrate. Med Klin 83:402–405.Google Scholar
  13. 13.
    Graham DY (1989) Campylobacter pylori as a pathogenic factor in duodenal ulcer: the case for. Scand J Gastroenterol [Suppl 160] 24:46–52.CrossRefGoogle Scholar
  14. 14.
    Graham DY (1989) Campylobacter pylori and peptic ulcer disease. Gastroenterology 96:615–625.PubMedGoogle Scholar
  15. 15.
    Graham DY, Lew GM, Michaletz PA (1989) Randomized controlled trial of the effect of eradication of C. pylori on ulcer healing and relapse. Gastroenterology 96: A 181.Google Scholar
  16. 16.
    Humphreys H, Bourke S, Dooley C, McKenna D, Power B, Keane CT, Sweeney EC, O’Morain C (1988) Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial. Gut 29:279–283.PubMedCrossRefGoogle Scholar
  17. 17.
    Lambert JR, Borromeo M, Korman MG, Hansky J, Eaves ER (1987) Effect of colloidal bismuth (De-Nol) on healing and relapse of duodenal ulcers — role of Campylobacter pyloridis. Gastroenterology 92:1489.Google Scholar
  18. 18.
    Marshall BJ (1989) Antimicrobial therapy of duodenal ulcer? Hold off for now. Reply. Gastroenterology 97:510.Google Scholar
  19. 19.
    Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, Phillips M, Waters TE, Sanderson CR (1988) Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet II:1437–1442.CrossRefGoogle Scholar
  20. 20.
    Smith AC, Price AB, Borriello P, Levi AJ (1988) A comparison of ranitidine and tripotassium dicitrato-bismuth (T.D.B.) in relapse rates of duodenal ulcer. The role of Campylobacter pylori (C.P.) Gastroenterology 94:A431.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • G. Börsch
    • 1
  1. 1.Department of Medicine, Elisabeth-HospitalAcademic Teaching Hospital of the University of Essen Medical SchoolEssenGermany

Personalised recommendations